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cation possession was 28% and number of days covered was 131
using unadjusted days supply estimate. Compared to LAT, odds
of achieving medication possession at year’s end were 26%–34%
lower for BIM and 34%–36% lower for TRAV (p  0.001 for all
comparisons for each imputation). Days covered were 21–29
days lower for BIM and 33–42 days lower for TRAV (p  0.001
for all comparisons). Failure to reﬁll a 2.5 mL size bottle within
the ﬁrst 90 days had 90%–99% speciﬁcity for predicting < 75%
days covered. CONCLUSION: Persistence with ocular prostag-
landins remains a concern. LAT users were more likely to achieve
medication possession and had more days covered during the
ﬁrst therapy year than those treated with BIM or TRAV. Failure
to reﬁll the index agent within the initial 90 days predicted poor
persistence.
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OBJECTIVE: To examine the relationship between distance
visual acuity (DVA) and self-reported vision-related quality of life
in NV-AMD subjects. METHODS: Baseline data from 113 sub-
jects completing 30 weeks in the PERSPECTIVES study, a multi-
center, multi-national 102-week clinical trial for the treatment of
NV-AMD, were reviewed. Vision function of the better-seeing
eye based on DVA (ETDRS letters at 2m), near vision (Bailey-
Lovie logMAR scores at 25cm), reading speed (words/minute at
25cm), and contrast sensitivity (Pelli-Robson logMAR score at
1m) were all measured. Vision-related quality of life (VR-QOL)
was collected using the National Eye Institute Visual Functioning
Questionnaire 25 (NEI-VFQ). Correlations were tested using
Pearson’s R, a = 0.05. RESULTS: Subject mean age was 74.0
years (8.0); 67 (59%) were female; and 109 (97%) were white.
DVA was signiﬁcantly correlated with the three clinical measures
of vision function (p < 0.001). DVA was also correlated with the
NEI-VFQ Distance Vision domain (p = 0.011) but not signiﬁ-
cantly associated with the Near Vision domain (p = 0.057). With
the exception of driving and color vision (p = 0.426 and
p = 0.135), the remaining domain scores were signiﬁcantly cor-
related with the DVA measure (range p = 0.029 to p = 0.001).
CONCLUSION: Some differences in self-reported VR-QOL can
be explained by DVA, while other effects on vision functioning
are less clear. Therefore, it may be preferable to use more than
one measure of vision function when assessing treatment effects.
PSS29
USTEKINUMAB IMPROVES DISEASE SPECIFIC
HEALTH-RELATED QUALITY OF LIFE IN PATIENTSWITH
MODERATETO SEVERE PSORIASIS: RESULTSWITHTHE
DERMATOLOGY LIFE QUALITY INDEX
Lebwohl M1, Papp K2, Schenkel B3, Eisenberg D3,Yeilding N4,
Guzzo C4,Wang Y4, Li S4, Krueger GG5
1Mount Sinai School of Medicine, New York, NY, USA, 2Probity
Medical Research,Waterloo, ON, Canada, 3J&J Pharmaceutical
Services L.L.C, Horsham, PA, USA, 4Centocor Research and
Development, Inc, Malvern, PA, USA, 5University of Utah Health
Sciences Center, Salt Lake City, UT, USA
OBJECTIVE: To evaluate the effects of ustekinumab on disease
speciﬁc HRQoL in psoriasis patients. METHODS: A total of 765
patients were enrolled in the PHOENIX I study. Patients were
randomized 1:1:1 to receive placebo, ustekinumab 45 mg, or
ustekinumab 90 mg. In the ustekinumab groups,patients received
treatment at weeks 0,4,16, and every 12 weeks thereafter.
Patients randomized to placebo at baseline crossed-over to
receive either 45 mg or 90 mg of ustekinumab at week 12.
Disease speciﬁc HRQoL was assessed using the Dermatology
Life Quality Index (DLQI). RESULTS: Baseline DLQI scores
were similar among treatment groups. The baseline mean
(median) total DLQI score was 11.5 (10.0). At week 2, the
combined ustekinumab group had signiﬁcantly greater improve-
ments (p < 0.001) from baseline in DLQI scores compared to the
placebo group. All placebo-treated patients crossed over to
receive ustekinumab at Week 12 and had comparable DLQI
improvements to the groups originally randomized to receive
ustekinumab. The mean (median) change from baseline score to
week 12 was –8.0 (-6.0) for the 45 mg group and –8.7 (-7.0) for
the 90 mg group, compared with –0.6 (0.0) for the placebo
group. At week 12, the proportion of patients who achieved a
clinically meaningful improvement (decrease of 5 or more points;
Kimball et al, 2004) was 64.6% in the 45 mg group and 71.1%
in the 90 mg group, compared to 17.9% in the placebo group.
Improvements were also demonstrated by the statistically signiﬁ-
cant proportion of patients in the 45 and 90 mg ustekinumab
groups who achieved a DLQI of 0 (32.7% and 34.0%, respec-
tively), as compared to the proportion of patients in the placebo
group (0.8%). CONCLUSION: Treatment with ustekinumab
45 mg or 90 mg resulted in signiﬁcantly improved disease speciﬁc
HRQoL compared with placebo in patients with moderate to
severe psoriasis, as measured by the DLQI.
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OBJECTIVE: To report the impact of ustekinumab on quality of
life(QOL)in psoriasis. METHODS: PHOENIX 2 was a multi-
center,randomized, double-blind, placebo-controlled, trial in
which 1230 psoriasis patients were randomized to receive sub-
cutaneously administered ustekinumab (45or 90 mg 4 weeks
apart, then q12 weeks thereafter) or placebo. Patients changed to
receive 45 or 90 mg ustekinumab at Weeks 12 and 16. Impact on
QOL, anxiety, depression, job performance, and work produc-
tivity were assessed using the Dermatology Life Quality Index
(DLQI), Hospital Anxiety and Depression Scale (HADS), and
Work Limitations Questionnaire(WLQ). RESULTS: DLQI
improvements from baseline were apparent by Week 4 (6.9 for
45 mg and 7.0 for 90 mg versus 1.4 for placebo; each p < 0.001
versus placebo). At Week 12, improvement in DLQI was 9.3 and
10.0 in the 45 and 90 mg groups, compared to 0.5 for place-
bo(each p < 0.001 versus placebo). DLQI improvement was
maintained through Week 24 (9.5 in 45 mg group and 10.3 in
90 mg group). Patients randomized to placebo experienced
improvements in DLQI 12 weeks after changing to ustekinumab.
At Week 12, 36.7%, and 39.1% of patients receiving 45 and
90mg, achieved a DLQI score of 0, indicating no impact of the
disease on patients’ QOL, compared with 1.0% receiving place-
bo(each p < 0.001 versus placebo). At Week 12, 71.8% of
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